Nanovibronix Inc - NAOV STOCK NEWS

NanoVibronix, Inc. (NASDAQ: NAOV) has filed a U.S. patent application for a new transdermal patch designed to deliver therapeutic agents, including cannabidiol (CBD), in combination with ultrasound technology from its PainShield® device. The innovation aims to enhance drug delivery and absorption, particularly for pain relief and anti-inflammatory effects. CEO Brian Murphy highlighted the potential benefits of this technology in providing alternative pain management solutions. The company aims to expand its patent portfolio and leverage its Surface Acoustic Wave technology for future growth.

NanoVibronix, Inc. (NASDAQ: NAOV) announced an increase in its public offering of common stock to 1,794,783 shares, priced at $1.00 each, due to strong demand. The offering is expected to close around September 25, 2020, raising approximately $1.8 million in gross proceeds before expenses. The funds will be used for working capital, including transitioning manufacturing from China to the U.S. and purchasing inventory. H.C. Wainwright & Co. is the sole book-running manager for this offering.

NanoVibronix, Inc. (NASDAQ: NAOV) announced an underwriting agreement with H.C. Wainwright to offer 1.5 million shares at $1.00 each, aiming to raise approximately $1.5 million by September 25, 2020. The proceeds will support the transition of manufacturing from China to the U.S. and inventory purchases. Additionally, the underwriter has a 30-day option for 225,000 more shares. This is part of a 'shelf' registration effective since August 2020. The offering does not constitute a sale in jurisdictions where it would be unlawful prior to registration.

NanoVibronix, Inc. (NASDAQ: NAOV) has received FDA Enforcement Discretion allowing the distribution of its UroShield device in the U.S. The device, intended to reduce catheter-associated urinary tract infections (CAUTI) and discomfort, addresses a significant healthcare need, particularly during the COVID-19 pandemic. This clearance significantly expands the company's market potential for UroShield, which demonstrates positive clinical evidence in preventing CAUTI. CEO Brian Murphy emphasizes its unique position in the market, given the urgent need for effective solutions amidst increasing urinary catheter use in hospitals.

NanoVibronix, Inc. (NASDAQ: NAOV) has successfully closed its public offering of 4,531,434 shares at $0.75 per share, resulting in gross proceeds of approximately $3.4 million. The offering included the underwriter's exercised option for an additional 198,100 shares. The funds will support working capital and facilitate transitioning manufacturing from China to the United States. H.C. Wainwright & Co. was the book-running manager for this transaction, which was conducted under an effective shelf registration statement.

NanoVibronix, Inc. (NASDAQ: NAOV) announced an increase in its public offering to 4,333,334 shares at $0.75 each due to high demand, with expected gross proceeds of approximately $3.25 million. The offering's closing is set for August 27, 2020, pending customary conditions. The underwriter, H.C. Wainwright & Co., holds a 30-day option for an additional 650,000 shares. Proceeds will support working capital and transition manufacturing from China to the U.S. The offering is made under an effective SEC registration statement.

NanoVibronix, Inc. (NASDAQ: NAOV) announced an underwriting agreement with H.C. Wainwright & Co. to sell 3,333,334 shares of common stock at $0.75 per share. The offering, expected to close around August 27, 2020, aims to raise approximately $2.5 million. The proceeds will be allocated for working capital and transitioning manufacturing from China to the United States. Additionally, the underwriter has a 30-day option to purchase up to 500,000 more shares. The offering is registered under Form S-3 with the SEC.

NanoVibronix, Inc. (NASDAQ: NAOV) has commenced shipments of its new UroShield® device to the UK. The company is collaborating with the National Institute of Clinical Evidence (NICE) to prepare for submission for official guidance, aiming to enhance access for NHS patients at risk of catheter-associated urinary tract infections (CAUTI). UroShield® is designed to prevent bacterial colonization in urinary catheters, thus reducing CAUTI rates and associated hospital stays. The company is also pursuing regulatory approvals in Australia and other markets.

NanoVibronix, Inc. (NASDAQ: NAOV) has signed a two-year exclusive distribution agreement with Ultra Pain Products, Inc. for its PainShield™ devices, effective June 22, 2020. This partnership aims to enhance access to opioid-free pain management solutions across the U.S. during the COVID-19 pandemic. The agreement stipulates the distribution of the newest PainShield model under specific pricing and order quantity requirements. The PainShield ultrasound device promises effective pain relief and soft tissue healing, catering to both home and clinical usage.